Ophthotech Corporation has received $-1.55 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 5 Financial Advisor in the Stock Trading Firms. Among 5 Analysts, Bottom line EPS Estimate for the current quarter is $-1.74 while the top line estimate is $-1.19 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -52.16%.
Ophthotech Corporation results fell short with a surprise EPS of -6.88% or $-0.11. The Actual EPS was $-1.71 compared to the Estimated EPS of $-1.6 during its most recent quarterly earnings.
In the last quarter, Ophthotech Corporation reported Annual Earnings of $-1.71. Based on the filings, last years Annual Earnings was, $-3.06. In the last Quarter, OPHT reported a surprise Earnings per Share of -6.88% . The consensus estimate for current quarter is $-1.55 and for the current fiscal year, the estimate is $-5.14. For the Next fiscal year, the estimate is $-3.24 based on the consensus.
Ophthotech Corporation (NASDAQ:OPHT) : On Tuesday heightened volatility was witnessed in Ophthotech Corporation (NASDAQ:OPHT) which led to swings in the share price. The stock opened for trading at $4.51 and hit $4.77 on the upside , eventually ending the session at $4.76, with a gain of 5.31% or 0.24 points. The heightened volatility saw the trading volume jump to 1,773,731 shares. The 52-week high of the share price is $65.96 and the company has a market cap of $170 million. The 52-week low of the share price is at $4.27 .
Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered in New York.